TY - CHAP
T1 - Insights into the Pathobiology of Secondary AML
AU - Jain, Tania
AU - Rampal, Raajit K.
N1 - Publisher Copyright:
© 2021, Springer Nature Switzerland AG.
PY - 2021
Y1 - 2021
N2 - Secondary acute myeloid leukemia (s-AML) is recognized as AML arising from prior hematological disease, usually myelodysplastic syndrome, myeloproliferative neoplasm, or aplastic anemia or has myelodysplasia related changes or develops in context of prior cytotoxic or radiation therapy. Understanding the biology of s-AML is of utmost importance as this portends a high-risk disease including a potential for lower responses to chemotherapy. Some therapeutic developments in recent times have been CPX-351 as well as venetoclax-containing combinations. Of particular ongoing and forthcoming interest is the role of targeted therapy itself or in combination with other agents. Lastly, the role of allogeneic stem cell transplantation remains crucial although debated, and with improvement in treatment strategies provides opportunities to use the two in combination for best results.
AB - Secondary acute myeloid leukemia (s-AML) is recognized as AML arising from prior hematological disease, usually myelodysplastic syndrome, myeloproliferative neoplasm, or aplastic anemia or has myelodysplasia related changes or develops in context of prior cytotoxic or radiation therapy. Understanding the biology of s-AML is of utmost importance as this portends a high-risk disease including a potential for lower responses to chemotherapy. Some therapeutic developments in recent times have been CPX-351 as well as venetoclax-containing combinations. Of particular ongoing and forthcoming interest is the role of targeted therapy itself or in combination with other agents. Lastly, the role of allogeneic stem cell transplantation remains crucial although debated, and with improvement in treatment strategies provides opportunities to use the two in combination for best results.
KW - Acute myeloid leukemia
KW - Myelodysplastic syndrome
KW - Myeloproliferative neoplasm
UR - http://www.scopus.com/inward/record.url?scp=85092649985&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092649985&partnerID=8YFLogxK
U2 - 10.1007/978-3-030-53633-6_3
DO - 10.1007/978-3-030-53633-6_3
M3 - Chapter
AN - SCOPUS:85092649985
T3 - Hematologic Malignancies
SP - 57
EP - 68
BT - Hematologic Malignancies
PB - Springer Science and Business Media Deutschland GmbH
ER -